Molina-Ruiz Rosa M, Martín-Carballeda Julia, Asensio-Moreno Inmaculada, Montañés-Rada Francisco
1 Department of Psychiatry, Fundación Alcorcón University Hospital-Public Health Agency, Madrid, Spain.
2 Psychiatry Department, Universidad Rey Juan Carlos de Madrid, Madrid, Spain.
Int J Psychiatry Med. 2017 Mar;52(2):176-189. doi: 10.1177/0091217417720896.
Background Subjects with intellectual disability are at increased risk of having comorbid psychiatric disorders and worse response to psychotherapeutic and psychopharmacological treatment interventions. On the other hand, available data on best treatment approach in this population are scarce and lack scientific evidence due to methodological limitations. The present study aims to perform a systematic review of the literature to facilitate the use of psychotropic drugs in clinical practice and better establish future research targets in this field. Objectives To review the available psychopharmacological strategies for patients with intellectual disabilities, psychiatric disorders, and behavioural disturbances. Serve as a quick guide for clinicians working in the field of intellectual disability. Methods We conducted a selective evidence-based review of the literature using Pubmed and EMBASE databases and selected most recent and relevant papers for this review. Results There are several available psychotropic drugs for the treatment of patients with intellectual disability and comorbid psychiatric disorders, although scientific evidence is limited. Treatment should be individualized according to risk-benefit balance. Discussion Further studies are needed and new available drugs should be considered to gain knowledge in effectiveness of different therapeutic approaches available in this population.
智力残疾患者患合并精神疾病的风险增加,对心理治疗和精神药物治疗干预的反应较差。另一方面,由于方法学上的局限性,关于该人群最佳治疗方法的现有数据稀缺且缺乏科学证据。本研究旨在对文献进行系统综述,以促进精神药物在临床实践中的应用,并更好地确定该领域未来的研究目标。
回顾针对智力残疾、精神疾病和行为障碍患者的现有精神药物治疗策略。为从事智力残疾领域工作的临床医生提供快速指南。
我们使用PubMed和EMBASE数据库对文献进行了基于证据的选择性综述,并为本综述选择了最新和相关的论文。
有几种精神药物可用于治疗智力残疾合并精神疾病的患者,尽管科学证据有限。治疗应根据风险效益平衡进行个体化。
需要进一步研究,并应考虑新的可用药物,以了解该人群中不同治疗方法的有效性。